NCT02328014 2025-12-09
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
Acerta Pharma BV
Phase 1/2 Completed
Clinical Trials
4 trialsNCT04402138 2025-05-13
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT03571308 2023-09-28
ACCEPT
University Hospital Southampton NHS Foundation Trust
Phase 1/2 Completed
NCT03527147 2022-08-15
PRISM
Acerta Pharma BV
Phase 1 Completed